Polycythemia Vera (PV) is a rare hematological malignancy estimated to affect approximately 50 thousand patients in the United States. Based on patient’s age and prior clinical history patients can be classified into low- and high-risk PV; based on this classification, the treatment approach and patient’s prognosis are different. Pharmacologic treatment of PV patients includes hydroxyurea, interferons and ruxolitinib (Incyte’s Jakafi), and is considered adequate for a relatively large group of patients. However, there is not a curative therapy, and there is an unmet need for certain population segments. As such, there is a commercial opportunity for therapies that are able to differentiate form the current standard of care.
- What are the key areas of unmet need and opportunity in the PV market?What is the approximate size of the diagnosed PV population in the United States?
- What is the expected impact of novel therapy launches, especially drugs with novel mechanisms of action?How does each current and future player influence the market and how will this change in the future?
- What are the key drivers and limiters of the PV market?
- Geography: United States
- Primary Research: Three KOL interviews in May 2019
- Key Companies Covered: Incyte, Merck & Co., Roche/Genentech, Kartos Therapeutics, PharmaEssentia, ItalfarmacoKey
- Drugs Covered: Ruxolitinib, Jakafi, interferons, KRT-232, idasanutlin, ropeginterferon α-2b, givinostat
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
- Executive Insights (US)
- Polycythemia Vera Executive Insights
Author(s): Nuno Tiago Giao Antunes, PhD; Atul Sharma, MPH
Nuno T. Antunes, , is senior business insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in antibacterial agents. Previously, he was a Latin America Market Access senior analyst in the Global Market Access Insights Team, where he developed expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Nuno holds a in animal health from the Universidad de las Palmas de Gran Canaria, Spain, and a degree from the Universidade de Trás-os-Montes e Alto Douro, Portugal. Prior to joining DRG, he conducted research in antimicrobial resistance and antimicrobial development, and worked in the medical devices industry as a scientist.
Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.